Describe the process(es) your organization has in place to ensure that your engagement activities are consistent with your overall climate change strategy[…]We participate in activities of the Federation of Pharmaceutical Manufacturers' Associations of Japan (FPMAJ) through our membership in the Japan Pharmaceutical Manufacturers' Association, an FPMAJ member. FPMAJ is member of the Japan Business Federation (KEIDANREN), which supports the Japanese Government's "2050 Carbon Neutral Declaration", has expressed its determination to work together with the Government to achieve it and drawn up a "Carbon Neutral Action Plan". Based on this plan, FPMAJ has drawn up "Action Plan for a Low-Carbon Society*4" and is promoting reductions in CO2 emissions. Sumitomo Pharma is a participant in this plan.
*4 CO2 reduction goals in Action Plan for Low-Carbon Society
PhaseⅠ:Reduce fiscal 2020 CO2 emissions by 23% based on fiscal 2005.
PhaseⅡ:Reduce fiscal 2030 CO2 emission by 25% based on fiscal 2013. It was changed last year "Reduce fiscal 2030 CO2 emission by 46% based on fiscal 2013."
Also, in line with Japanese Government policy, FPMAJ is working on reducing emissions of chlorofluorocarbons, which are also GHGs, and has established "Chlorofluorocarbon Study Subcommittee", a specialist subcommittee. The subcommittee has drawn up a voluntary action plan including numerical goals and in addition to carrying out activities to control emissions of chlorofluorocarbon substitutes (HFCs) used in quantitative spray aerosols is supporting policy execution through regular reporting to the Industrial Structure Council of the Ministry of Economy, Trade and Industry. Since Sumitomo Pharma imports and sells Qvar®, an inhaled steroid asthma therapy containing HFC-134a as a propellant, we participate in subcommittee efforts to reduce HFCs and collaborate with the regulatory authorities.